ArticleFrontiers in physiology2017
Prognostic Values of Long Noncoding RNA GAS5 in Various Carcinomas: An Updated Systematic Review and Meta-Analysis.
Article in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Diagnostic and Prognostic Significance of RASSF8-AS1 lncRNA Expression in Non-Small Cell Lung Cancer.Bulletin of experimental biology and medicine · 2025Article
- Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate.Frontiers in genetics · 2022Article
- Circulating Long Non-Coding RNAs LINC00324 and LOC100507053 as Potential Liquid Biopsy Markers for Esophageal Squamous Cell Carcinoma: A Pilot Study.Frontiers in oncology · 2022Article
- The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.Molecular therapy. Nucleic acids · 2021Review
- Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL.Cancers · 2021Article
- Association between long non-coding RNA (lncRNA) GAS5 polymorphism rs145204276 and cancer risk.The Journal of international medical research · 2021Article
- Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis.Frontiers in oncology · 2021Article
- Developmental changes of rRNA ribose methylations in the mouse.RNA biology · 2020Article
- LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTENRSC advances · 2019Article
- A Brief Overview of lncRNAs in Endothelial Dysfunction-Associated Diseases: From Discovery to Characterization.Epigenomes · 2019Review
- miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.Non-coding RNA · 2019Article
- The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers.Journal of Cancer · 2019Article
- The CtBP1-HDAC1/2-IRF1 transcriptional complex represses the expression of the long noncoding RNA GAS5 in human osteosarcoma cells.International journal of biological sciences · 2019Article
- Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.British journal of cancer · 2018Article
- Clinical Values of Long Non-coding RNAs in Bladder Cancer: A Systematic Review.Frontiers in physiology · 2018Article
- Autophagy-Modulating Long Non-coding RNAs (LncRNAs) and Their Molecular Events in Cancer.Frontiers in genetics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth arrest-specific transcript 5 (GAS5) is a long noncoding RNA with low expression in multiple cancers. This meta-analysis aims to explore the association between GAS5 expression levels and cancer patients' prognosis. We collected all the relevant literatures about GAS5 expression levels associated with overall survival (OS), lymph node metastasis (LNM) and high tumor stage (II/III/IV) (HTS) from the PubMed and Web of Science. The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were calculated to evaluate the link strength between GAS5 and cancer prognosis. A total of 934 patients from 14 studies were included to the present meta-analysis, according to the inclusion and exclusion criteria. The results demonstrated that low expression of GAS5 could predict poor OS in cancer patients (HR = 1.955, 95% CI: 1.551-2.465,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.